Келесі

• 

  • 22:14
  • 1,5 М.

  Zanubrutinib - FDA Approval, Efficacy & Safety Profile in CLL - Discussion with Dr. Shadman
• 

  • 19:32
  • 1,9 М.

  Acalabrutinib And Zanubrutinib in CLL
• 

  • 00:45
  • 27 МЛН
  • 17 күн бұрын

  ОБЯЗАТЕЛЬНО СОВЕРШАЙТЕ ДОБРО!❤❤❤
• 

  • 00:55
  • 37 МЛН
  • 6 күн бұрын

  Can This Bubble Save My Life? 😱
• 

  • 00:10
  • 6 МЛН
  • 6 күн бұрын

  Fortunately, Ultraman protects me #shorts #ultraman #ultramantiga #liveaction
• 

  • 00:11
  • 12 МЛН
  • 6 күн бұрын

  Look at two different videos 😁 @karina-kola
• 

  • 18:44
  • 474

  Sjogren's: how I was diagnosed, my labs, tests, & lip biopsy
• 

  • 21:05
  • 2,1 М.

  ASH 2023 CLL/Lymphoma Highlights - ALPINE, SEQUOIA, SWOG-S1826, POLARIX Update | Dr. Mazyar Shadman
• 

  • 3:52
  • 297

  Clinical outcomes of patients with CLL treated with venetoclax-based regimens
• 

  • 4:10
  • 1,5 М.

  Reigniting Hope to Reclaim Movement
• 

  • 18:46
  • 1,2 МЛН

  Approach to the Exam for Parkinson's Disease
• 

  • 26:32
  • 2,2 М.

  How to Interpret Your CGM Data
• 

  • 45:50
  • 2,2 М.

  Treating Persistent/Chronic ITP Current Care, Future Potential
• 

  • 5:44
  • 1,3 М.

  ASH 2022: Zanubrutinib Demonstrates Superior PFS Compared with Ibrutinib for R/R CLL/SLL: Result...
• 

  • 2:57
  • 1,9 М.

  Selecting between ibrutinib, acalabrutinib and zanubrutinib in the frontline setting in CLL
• 

  • 3:51
  • 1,1 М.

  Knee Pain Explained - Lewis Nurney, Singapore Podiatrist
• 

  • 00:45
  • 27 МЛН
  • 17 күн бұрын

  ОБЯЗАТЕЛЬНО СОВЕРШАЙТЕ ДОБРО!❤❤❤